Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results.
OBJECTIVE
The safety and long-term results of directional coronary atherectomy in stented coronary arteries were determined. In addition, tissue studies were performed to characterize the development of restenosis.


METHODS
Directional coronary atherectomy was performed in restenosed stents in nine patients (10 procedures) 82 to 1,179 days after stenting. The tissue was assessed for histologic features of restenosis, smooth muscle cell phenotype, markers of cell proliferation and cell density. A control (no stenting) group consisted of 13 patients treated with directional coronary atherectomy for restenosis 14 to 597 days after coronary angioplasty, directional coronary atherectomy or laser intervention.


RESULTS
Directional coronary atherectomy procedures within the stent were technically successful with results similar to those of the initial stenting procedure (2.31 +/- 0.38 vs. 2.44 +/- 0.35 mm). Of five patients with angiographic follow-up, three had restenosis requiring reintervention (surgery in two and repeat atherectomy followed by laser angioplasty in one). Intimal hyperplasia was identified in 80% of specimens after stenting and in 77% after coronary angioplasty or atherectomy. In three patients with stenting, 70% to 76% of the intimal cells showed morphologic features of a contractile phenotype by electron microscopy 47 to 185 days after coronary intervention. Evidence of ongoing proliferation (proliferating cell nuclear antigen antibody studies) was absent in all specimens studied. Although wide individual variability was present in the maximal cell density of the intimal hyperplasia, there was a trend toward a reduction in cell density over time.


CONCLUSIONS
Although atherectomy is feasible for the treatment of restenosis in stented coronary arteries and initial results are excellent, recurrence of restenosis is common. Intimal hyperplasia is a nonspecific response to injury regardless of the device used and accounts for about 80% of cases of restenosis. Smooth muscle cell proliferation and phenotypic modulation toward a contractile phenotype are early events and largely completed by the time of clinical presentation of restenosis. Restenotic lesions may be predominantly cellular, matrix or a combination at a particular time after a coronary procedure.
Strauss
B H
BH
Catheterization Laboratory, Erasmus University, Rotterdam, The Netherlands.
Umans
V A
VA
van Suylen
R J
RJ
de Feyter
P J
PJ
Marco
J
J
Robertson
G C
GC
Renkin
J
J
Heyndrickx
G
G
Vuzevski
V D
VD
Bosman
F T
FT
D000199:Actins / Q000737:chemistry; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D017225:Atherectomy, Coronary / Q000379:methods / Q000592:standards*; D001530:Belgium; D001706:Biopsy; D002452:Cell Count; D002455:Cell Division; D017023:Coronary Angiography; D003327:Coronary Disease / Q000175:diagnosis / Q000453:epidemiology / Q000601:surgery*; D003936:Diagnosis, Computer-Assisted; D004867:Equipment Design / Q000592:standards; D005240:Feasibility Studies; D005260:Female; D005602:France; D006801:Humans; D006965:Hyperplasia; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000473:pathology / Q000648:ultrastructure; D009426:Netherlands; D009687:Nuclear Proteins / Q000737:chemistry; D010641:Phenotype; D018809:Proliferating Cell Nuclear Antigen; D012008:Recurrence; D012086:Reoperation / Q000379:methods / Q000592:standards*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
D000199:Actins; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen